Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression-Reference-Cited by-同舟云学术

Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression

Published:2018-08-01 Issue:10 Volume:235 Page:2859-2869
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Murasaki Mitsukuni,Koyama Tsukasa,Kanba Shigenobu,Takeuchi Masahiro,Shimizu Yuriko,Arita Eri,Kuroishi Kentaro,Takeuchi Masahiro,Kamei Shinya

Funder

Dainippon Sumitomo Pharma

Janssen Phrma (Jp)

Nippon Chemiphar

Mochida Pharmaceutical Company

Eisai

Pfizer Japan

Mitsubishi Tanabe Pharma (Jp)

Meiji Seika Pharma

Yoshitomiyakuhin (Jp)

Shionogi

Astellas Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/article/10.1007/s00213-018-4977-6/fulltext.html

Reference21 articles.

1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. Fourth (text revision) edn. American Psychiatric Association Publishing, Washington, DC

2. American Psychiatric Association (2013) Bipolar and related disorders. In diagnostic and statistical manual of mental disorders, Fifth edn. American Psychiatric Association Publishing, Washington, DC

3. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351–1360. https://doi.org/10.1176/appi.ajp.162.7.1351

4. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR (2008) A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 69:302–309

5. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 135:119–126

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders);Psychiatry and Clinical Neurosciences;2024-08-28

2. Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression;Pharmacopsychiatry;2024-06-19

3. All studies are not created equal: A systematic narrative review of bipolar depression clinical trial inclusion/exclusion rules and baseline severity scores;Journal of Affective Disorders;2023-07

4. ARIQUELI Study I: Should quetiapine monotherapy be considered for any acute presentation of bipolar disorder?;2023-03-14

5. Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review;International Clinical Psychopharmacology;2023-03-13